

Special Issue

Minimally Invasive Surgical Treatments in Kidney Cancer: Clinical Implications, Risk Assessment, and Outcomes

Message from the Guest Editors

This Special Issue is dedicated to exploring the advancements and implications of minimally invasive surgical treatments in kidney cancer. With the advent of robotic technology and the pursuit of improved patient outcomes, minimally invasive techniques have increasingly become the cornerstone of management in various medical disciplines, including uro-oncology. As kidney cancer remains a significant concern globally, it is imperative to understand the clinical implications of these interventions, accurately assess the associated risks, and evaluate the resultant outcomes. Through a compilation of robust original studies and reviews, this issue aims to bridge the gap in our understanding, shedding light on both the advantages and potential challenges posed by minimally invasive approaches in treating kidney cancer.

Guest Editors

Dr. Andrea Mari

Dr. Daniele Amparore

Dr. Riccardo Bertolo

Deadline for manuscript submissions

closed (30 November 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/185456

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)